Yannick Cyr1,2,3, Valérie Lamantia1,2,3, Simon Bissonnette1,2,3, Melanie Burnette1,3, Aurèle Besse-Patin1,2,3, Annie Demers4, Martin Wabitsch5, Michel Chrétien1,2,6, Gaétan Mayer5,7, Jennifer L Estall1,2,3, Maya Saleh8,9, May Faraj1,2,3. 1. Institut de recherches cliniques de Montréal (IRCM), Montréal, QC, Canada. 2. Faculty of Medicine, Université de Montréal, Montréal, QC, Canada. 3. Montreal Diabetes Research Center (MDRC), Montréal, QC, Canada. 4. Institut de cardiologie de Montréal (ICM), Montréal, QC, Canada. 5. Department of Pediatrics and Adolescent Medicine, Ulm University Hospital, Ulm, Germany. 6. Ottawa Health Research Institute (OHRI), Ottawa, ON, Canada. 7. Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada. 8. Department of Medicine, McGill University, Montréal, QC, Canada. 9. Department of Life Sciences and Health, The University of Bordeaux, Bordeaux, France.
Abstract
BACKGROUND: LDL-cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflammasome/interleukin-1 beta (IL-1β) pathway promotes white adipose tissue (WAT) dysfunction and type 2 diabetes (T2D) and is regulated by LDL receptors (LDLR and CD36). We hypothesized that: (a) normocholesterolemic subjects with lower plasma PCSK9, identifying those with higher WAT surface-expression of LDLR and CD36, have higher activation of WAT NLRP3 inflammasome and T2D risk factors, and; (b) LDL upregulate adipocyte NLRP3 inflammasome and inhibit adipocyte function. METHODOLOGY: Post hoc analysis was conducted in 27 overweight/ obese subjects with normal plasma LDL-C and measures of disposition index (DI during Botnia clamps) and postprandial fat metabolism. WAT was assessed for surface-expression of LDLR and CD36 (immunohistochemistry), protein expression (immunoblot), IL-1β secretion (AlphaLISA), and function (3 H-triolein storage). RESULTS: Compared to subjects with higher than median plasma PCSK9, subjects with lower PCSK9 had higher WAT surface-expression of LDLR (+81%) and CD36 (+36%), WAT IL-1β secretion (+284%), plasma IL-1 receptor-antagonist (+85%), and postprandial hypertriglyceridemia, and lower WAT pro-IL-1β protein (-66%), WAT function (-62%), and DI (-28%), without group-differences in body composition, energy intake or expenditure. Adjusting for WAT LDLR or CD36 eliminated group-differences in WAT function, DI, and postprandial hypertriglyceridemia. Native LDL inhibited Simpson-Golabi Behmel-syndrome (SGBS) adipocyte differentiation and function and increased inflammation. CONCLUSION: Normocholesterolemic subjects with lower plasma PCSK9 and higher WAT surface-expression of LDLR and CD36 have higher WAT NLRP3 inflammasome activation and T2D risk factors. This may be due to LDL-induced inhibition of adipocyte function.
BACKGROUND: LDL-cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflammasome/interleukin-1 beta (IL-1β) pathway promotes white adipose tissue (WAT) dysfunction and type 2 diabetes (T2D) and is regulated by LDL receptors (LDLR and CD36). We hypothesized that: (a) normocholesterolemic subjects with lower plasma PCSK9, identifying those with higher WAT surface-expression of LDLR and CD36, have higher activation of WAT NLRP3 inflammasome and T2D risk factors, and; (b) LDL upregulate adipocyte NLRP3 inflammasome and inhibit adipocyte function. METHODOLOGY: Post hoc analysis was conducted in 27 overweight/ obese subjects with normal plasma LDL-C and measures of disposition index (DI during Botnia clamps) and postprandial fat metabolism. WAT was assessed for surface-expression of LDLR and CD36 (immunohistochemistry), protein expression (immunoblot), IL-1β secretion (AlphaLISA), and function (3 H-triolein storage). RESULTS: Compared to subjects with higher than median plasma PCSK9, subjects with lower PCSK9 had higher WAT surface-expression of LDLR (+81%) and CD36 (+36%), WAT IL-1β secretion (+284%), plasma IL-1 receptor-antagonist (+85%), and postprandial hypertriglyceridemia, and lower WAT pro-IL-1β protein (-66%), WAT function (-62%), and DI (-28%), without group-differences in body composition, energy intake or expenditure. Adjusting for WAT LDLR or CD36 eliminated group-differences in WAT function, DI, and postprandial hypertriglyceridemia. Native LDL inhibited Simpson-Golabi Behmel-syndrome (SGBS) adipocyte differentiation and function and increased inflammation. CONCLUSION: Normocholesterolemic subjects with lower plasma PCSK9 and higher WAT surface-expression of LDLR and CD36 have higher WAT NLRP3 inflammasome activation and T2D risk factors. This may be due to LDL-induced inhibition of adipocyte function.
Authors: P W Connelly; M Poapst; J Davignon; S Lussier-Cacan; B Reeder; R Lessard; R A Hegele; A Csima Journal: Can J Cardiol Date: 1999-04 Impact factor: 5.223
Authors: Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford Journal: Lancet Date: 2010-02-16 Impact factor: 79.321
Authors: Martina I Lefterova; Yong Zhang; David J Steger; Michael Schupp; Jonathan Schug; Ana Cristancho; Dan Feng; David Zhuo; Christian J Stoeckert; X Shirley Liu; Mitchell A Lazar Journal: Genes Dev Date: 2008-11-01 Impact factor: 11.361
Authors: Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine Journal: N Engl J Med Date: 2016-12-01 Impact factor: 91.245
Authors: Peitao Wu; Jee-Young Moon; Iyas Daghlas; Giulianini Franco; Bianca C Porneala; Fariba Ahmadizar; Tom G Richardson; Jonas L Isaksen; Georgy Hindy; Jie Yao; Colleen M Sitlani; Laura M Raffield; Lisa R Yanek; Mary F Feitosa; Rafael R C Cuadrat; Qibin Qi; M Arfan Ikram; Christina Ellervik; Ulrika Ericson; Mark O Goodarzi; Jennifer A Brody; Leslie Lange; Josep M Mercader; Dhananjay Vaidya; Ping An; Matthias B Schulze; Lluis Masana; Mohsen Ghanbari; Morten S Olesen; Jianwen Cai; Xiuqing Guo; James S Floyd; Susanne Jäger; Michael A Province; Rita R Kalyani; Bruce M Psaty; Marju Orho-Melander; Paul M Ridker; Jørgen K Kanters; Andre Uitterlinden; George Davey Smith; Dipender Gill; Robert C Kaplan; Maryam Kavousi; Sridharan Raghavan; Daniel I Chasman; Jerome I Rotter; James B Meigs; Jose C Florez; Josée Dupuis; Ching-Ti Liu; Jordi Merino Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152